Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

Cancer types with lower mutational load and a non-permissive tumor microenvironment are intrinsically resistant to immune checkpoint blockade. While the combination of cytostatic drugs and immunostimulatory antibodies constitutes an attractive concept for overcoming this refractoriness, suppression...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Baumann, Daniel, Hägele, Tanja, Mochayedi, Julian, Drebant, Jennifer, Vent, Caroline, Blobner, Sven, Noll, Julia Han, Nickel, Irena, Schumacher, Corinna, Boos, Sophie Luise, Daniel, Aline Sophie, Wendler, Susann, Volkmar, Michael, Strobel, Oliver, Offringa, Rienk
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7195409/
https://ncbi.nlm.nih.gov/pubmed/32358491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-15979-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados